A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant (NCT07092865)
A Phase 2b, Non-randomized, Controlled, Open-label, Extension Study to Evaluate the Persistence of Immune Response of the Adjuvanted RSVPreF3 Vaccine and the Safety and Immunogenicity Following Revaccination in Lung and Kidney Transplant Recipients (>=18 Years of Age)
๐ฉบ Plain-English Summary (8th-Grade Level)
This study evaluates persistence of the immune response of the adjuvanted RSV vaccine and the safety and immunogenicity following revaccination in adults 18 years of age and above who received lung or kidney transplant.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site โ Lexington, Kentucky
Age range: 18 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (37 Sites)
Showing the first 25 of 37 sites.
- GSK Investigational Site โ Lexington, Kentucky
- GSK Investigational Site โ St Louis, Missouri
- GSK Investigational Site โ Omaha, Nebraska
- GSK Investigational Site โ New York, New York
- GSK Investigational Site โ Pittsburgh, Pennsylvania
- GSK Investigational Site โ Temple, Texas
- GSK Investigational Site โ Camperdown, New South Wales
- GSK Investigational Site โ Birtinya, Queensland
- GSK Investigational Site โ Herston, Queensland
- GSK Investigational Site โ Edmonton, Alberta
- GSK Investigational Site โ Vancouver, British Columbia
- GSK Investigational Site โ London, Ontario
- GSK Investigational Site โ Toronto, Ontario
- GSK Investigational Site โ Giessen,
- GSK Investigational Site โ Milan,
- GSK Investigational Site โ Milan,
- GSK Investigational Site โ Palermo,
- GSK Investigational Site โ Pavia,
- GSK Investigational Site โ Siena,
- GSK Investigational Site โ Aichi,
- GSK Investigational Site โ Aichi,
- GSK Investigational Site โ Fukuoka,
- GSK Investigational Site โ Hyลgo,
- GSK Investigational Site โ Kumamoto,
- GSK Investigational Site โ Okayama,
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Respiratory Syncytial Virus Infections
- Effectiveness of Immunization in Preventing Severe Acute Respiratory Infection RSV in Children Under 6 Months in Bogotรก โ Bogotรก,
- Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above โ Mobile, Alabama
- An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study โ Birmingham, Alabama
- A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease โ Los Angeles, California
- A Study of BLB-201 RSV Vaccine in Infants and Children โ La Mesa, California
Explore by condition: All Respiratory Syncytial Virus Infections clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.